Molecular Neurobiology

, Volume 36, Issue 1, pp 45–59

Cannabinoids and Multiple Sclerosis



This review discusses clinical and preclinical evidence that supports the use of cannabinoid receptor agonists for the management of multiple sclerosis. In addition, it considers preclinical findings that suggest that as well as ameliorating signs and symptoms of multiple sclerosis, cannabinoid CB1 and/or CB2 receptor activation may suppress some of the pathological changes that give rise to these signs and symptoms. Evidence that the endocannabinoid system plays a protective role in multiple sclerosis is also discussed as are potential pharmacological strategies for enhancing such protection in the clinic.


Δ9-tetrahydrocannabinol Dronabinol Marinol® Sativex® Nabilone Cesamet® Multiple sclerosis Spasticity Pain Cannabinoid receptors Endocannabinoids Anandamide 2-arachidonoyl glycerol 

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  1. 1.School of Medical Sciences, Institute of Medical SciencesUniversity of AberdeenAberdeenUK

Personalised recommendations